Asahi Kasei Bioprocess America (AKBA) is devoted to solving therapeutic product safety, efficiency and purity challenges within the pharmaceutical and bioprocessing industries. With technology platforms for virus filtration, chromatography, inline buffer formulation and oligonucleotide synthesis, our bioprocessing systems, columns and automation solutions advance GMP manufacturing of critical drug substances around the world. By focusing our expertise on fluid management technology, our portfolio of market-driven equipment and cutting-edge technology touches unit operations across a wide range of therapeutic modalities, including classical small molecule pharmaceuticals, current-generation antibodies, plasma derivatives and next-generation oligonucleotide therapeutics.
Asahi Kasei Bioprocess is committed to providing high quality and innovative equipment and filtration solutions by delivering what customers need, continuously improving processes and living by our values every day.
In this podcast, we spoke with Chris Rombach, Vice President of Sales and Marketing at Asahi Kasei Bioprocess America about buffer prep and delivery systems. We discussed current pain points and how next generation buffer prep solutions can greatly improve upon the status quo, including increasing the use of automation and remote operation, while reducing the overall footprint, labor and cost associated with more traditional approaches. ...Continued